Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.

  title={Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.},
  author={A Falco and Filippo Salvati and Ester Vitacolonna and Giuseppe Avellone and Antonio Pinto and Concetta Di Febbo and Enzo Ballone and Marta Di Nicola and Giovanni Ciabattoni and Giovanni Davı̀},
  volume={183 2},
Triflusal is an antiplatelet drug related to aspirin, with different pharmacological properties and a lower haemorrhagic risk. We aimed at comparing their effects on platelet and endothelial activation in type 2 diabetes mellitus (T2DM). In a randomized, double-blind, parallel group study, we compared the effects of three daily regimens (300, 600, and 900 mg) of triflusal, and aspirin (100mg/day) on urinary 11-dehydro-thromboxane (TX)B(2), index of in vivo platelet activation, ex vivo platelet… Expand
4 Citations
Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review.
It is indicated that about one quarter of people receiving aspirin would be identified--as an average--as aspirin non-responders by PFA-100, a point-of-care device, and efforts to better standardize it and to control for its major methodological variables might be useful to improve monitoring of platelet performance under aspirin treatment. Expand
A Critical Review of Aspirin in the Secondary Prevention of Noncardioembolic Ischaemic Stroke
It is shown that the benefit from aspirin treatment is consistently shown in ischaemic stroke, while harms are limited, and no definite superiority is apparent across different antiplatelet therapies. Expand
Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.
Triflusal has a role in the primary prevention of cerebrovascular events in atrial fibrillation, and for the secondary prevention of cerebral and myocardial infarction, primarily as an alternative to aspirin in patients for whom aspirin is unsuitable. Expand
Antiagregantes plaquetarios: mecanismos de acción y riesgos asociados al uso
En esta revision, se abordan diversos aspectos relativos a los antiagregantes, especialmente mecanismo de accion y riesgos asociados al uso durante los ultimos 10 anos. Expand


Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients
A study was made on the inhibitory effect of triflusal and acetylsalicylic acid on platelet aggregation in whole blood and platelet‐rich plasma induced by ADP, in 30 insulin‐dependent diabetic patients without vascular complications. Expand
Thromboxane biosynthesis and platelet function in type II diabetes mellitus.
The fact that thromboxane biosynthesis recovered over the following 10 days was consistent with a platelet origin of the urinary metabolite and platelet function in 50 patients with Type II diabetes mellitus who had normal renal function and clinical evidence of macrovascular disease. Expand
Platelet antiaggregatory effect of triflusal in human whole blood.
The results suggest an important role of red blood cells and/or leukocytes in the mechanism of action of triflusal and its main metabolite HTB, and that inhibition of platelet cyclooxygenase by HTB masks its negative interaction with trifLusal. Expand
In Vivo Formation of 8-Iso-Prostaglandin F2α and Platelet Activation in Diabetes Mellitus
Vitamin E supplementation, metabolic control, and cyclooxygenase inhibitors were used to investigate the mechanisms of formation of the F2-isoprostane 8-iso-PGF2α in this setting. Expand
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs.
The capacity of platelets to generate thromboxane A2, reflected by measurement of serum thromboxane B2 (TxB2), greatly exceeds the systemic production of thromboxane in vivo. Thus, it is possibleExpand
Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers.
The ex vivo effect of triflusal and acetylsalicylic acid (ASA) on platelet interaction with the subendothelium using the Baumgartner perfusion system (wall shear rate 350 s−1) was assessed in bloodExpand
Comparison of in vitro effects of triflusal and acetysalicylic acid on nitric oxide synthesis by human neutrophils.
It is indicated that it is possible to develop new and more potent acetylsalicylic acid-related antiplatelet drugs for the prevention of the myocardial ischemic/reperfusion processes. Expand
Influence of triflusal on platelet activation after coronary artery bypass graft.
Investigation of the effects of the antiplatelet agent triflusal on the changes in platelet function in patients who underwent a cardiopulmonary bypass for coronary arteries found it reduces platelet activation caused by the coronary artery bypass graft surgery. Expand
Clinical pharmacology of platelet cyclooxygenase inhibition.
Whether a selective sparing of extraplatelet cyclooxygenase activity by low-dose aspirin will result in increased antithrombotic efficacy, fewer toxic reactions, or both remains to be established in prospective clinical trials. Expand
Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.
Acetylation of platelet cyclooxygenase by oral aspirin is dose dependent and cumulative with repeated administration. However, no single dose of aspirin has been found to be completely selective ofExpand